knowledge -WSS

knowledge

author：fashion 2025-10-04 07:30:16 - browse：171

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare proposal to cover medical devices draws a mixed reaction

explore

focus

WSS

FDA does about

The high cost of giving birth even with insurance

Why getting cancer drugs just got harder for rural patients

A Q&A with Aletha Maybank, AMA’s chief health equity officer

How to fix the rural physician shortage in the U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Alkermes shareholders re

Kenai launches with $82 million for Parkinson’s stem cell therapy

Trump demands the U.S. pay no more for drugs than other countries … again

Jerome Adams on the need for new antivirals for Covid

Hollywood unions extend contract negotiations for actors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

DIEP, the 'gold standard' of breast reconstruction, is under threat

Obesity now affects over 1 billion people worldwide, study finds

23andMe had bad news about my health. I wish a person had delivered it

Activists slam private health insurers over coverage restrictions

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

At least 13 dead in Texas as scorching temps continue

An inside look at PIPEs, biotech's buzzy new financing tool

A Q&A with Aletha Maybank, AMA’s chief health equity officer

House looks to weaken Medicare negotiation

Apple is now the first public company to be valued at $3 trillion

explore

explore

focus

hotspot